Merck Says FDA Accepts Its sBLA For Keytruda And Grants Priority Review
April 13, 2016 at 08:04 AM EDT
Merck & Co., Inc. (NYSE: MRK) said the FDA has accepted its supplemental Biologics License Application (sBLA) for its Keytruda, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.